Introduction: Myasthenia is a rare and disabling autoimmune disease. Few studies were devoted to this pathology. We report a clinical case of myasthenia in the Department of Internal Medicine at the Point G University Teaching Hospital. Observation: This is a 41-year-old patient of Malian origin, a trader with a history of hemorrhoidectomy in 2011 and familial hypertension, was admitted on August 19, 2014, for muscle weakness, dysphonia, and dysphagia. The disease started 1 year before admission at the department with progressive muscle weakness of the upper limbs aggravated by repetitive movements and spreading to the head “drooping head” and inferior limbs, associated with general fatigue, dysphonia and selective dysphagia for solid foods. The diagnosis of myasthenia was maintained based on the clinical signs such as ptosis, bilateral diplopia, and weakness with lower limbs muscle strength rated at 3/5, and confirmed with confirmatory exams; a positive anti-acetylcholine receptor antibody (RIA), the post-synaptic neuromuscular conduction block at ENMG and the positive neostigmine pharmacological test. The patient received Neostigmine (prostagmine) 0.5 mg one ampoule in IM/day and Prednisone at a dosage of 1 mg/kg/day. The evolution was marked by a moderate improvement of the symptomatology afterward the patient was evacuated to Tunisia on family request where he received a course of immunoglobulin 2 g/kg in 2 days. The evolution in Tunisia was favorable. The patient returned in Mali and death occurred after 2 months in a context of respiratory distress. Conclusion: Myasthenia is a rare but serious disease requiring careful management and monitoring to reduce respiratory complications.
References
[1]
Meriggioli, M.N. and Sanders, D.B. (2005) Advances in the Diagnosis of Neuromuscular Junction Disorders. American Journal of Physical Medicine & Rehabilitation, 84, 627-638. https://doi.org/10.1097/01.phm.0000171169.79816.4c
[2]
Mekrani, S. and Brignol, T.N. (2006) Autoimmune Myasthenia 10/2006.
[3]
Hyung, S.L., Hye, S.L., et al. (2016) The Epidemiology of Myasthenia Gravis in Korea, Departments of Neurology and Biostatistics, Yonsei University College of Medicine, Seoul, Korea. Yonsei Medical Journal, 57, 419-425.
https://doi.org/10.3349/ymj.2016.57.2.419
[4]
Sacko, M. (2016) Clinical, Paraclinical, and Therapeutic Aspects of Autoimmune Myasthenia Gravis in the Neurology Department of the Point G University Teaching Hospital. Thesis.
[5]
Erkan, D., Cervera, R. and Asherson, R.A. (2003) Catastrophic Antiphospholipid Syndrome: Where Do We Stand? Arthritis & Rheumatology, 48, 3320-3327.
https://doi.org/10.1002/art.11359
[6]
Juel, V.C. and Massey, J.M. (2007) Myasthenia Gravis. Orphanet Journal of Rare Disease, 2, 44. https://doi.org/10.1186/1750-1172-2-44
[7]
Eymard, B. (2014) Myasthenia on the Side of the Internist. La Revue de Médecine Interne, 35, 421-429. https://doi.org/10.1016/j.revmed.2013.08.013
[8]
Grob, D., Arsura, E.L., Brunner, G. and Namba, T. (1987) The Race of Myasthenia Gravis and Therapies Affecting the Outcome. Annals of the New York Academy of Science, 505, 472-499. https://doi.org/10.1111/j.1749-6632.1987.tb51317.x
[9]
Barbaud, A., et al. (2006) Late Forms of Myasthenia; Comparative Study with Myasthenia of the Young Subject. Revista de Neurología, 162, 990-996.
https://doi.org/10.1016/S0035-3787(06)75109-8
[10]
Linda, R., et al. (2017) Autoimmune Myasthenia Jacks-Up and Therapeutic Management of the Pharmacy; Memory Ended Studies to Obtain the Diplomas of Doctor of Pharmacy, 05/15/2017, Algeria.
[11]
Gajdos, P. (2004) Myasthenia Seronegative. Revista de Neurología, 160, 159-162.
https://doi.org/10.1016/S0035-3787(04)70886-3
[12]
Saraux-Bonneton, A., et al. (2001) D'une observation; Département de gériatrie, hôpital Vaugirard-Gabriel-Pallez. Revista de Internal, 22, 984-987.
[13]
Dechy, H., Wechsler, B., Hausfater, P., et al. (2017) Neurological Disorders in Systemic Diseases. 72-77.
[14]
Hall-Besnier, D. (2010) Traitement de la myasthénie auto-immune; Département de neurologie, Centre de référence pour les maladies neuromusculaires, Hôpital Universitaire d'Angers. Revista de Neurología, 166, 400-405.
[15]
Seybold, M.E. (1987) Plasmapheresis in Myasthenia Gravis. Annals of the New York Academy of Sciences, 505, 584-587.
https://doi.org/10.1111/j.1749-6632.1987.tb51326.x
[16]
Van der Meche, F.G. and Van Dorn, P.A. (1997) The Current Place of High Dose Immunoglobulin in the Treatment of Neuromuscular Disorders. Muscle & Nerve, 20, 136-147.
https://doi.org/10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D
[17]
Goblin, C. and Gajdos, P. (2002) Myasthenia and Myasthenic Syndromes. Encyclical Med Chir, Editions Scientifiques et Medicales Elsevier SAS, Paris, Neurology, 17-172-B-10, 14 p.